The share price of pharmaceutical company Wockhardt jumped over 2 percent intraday on October 1 after CARE had revised long term bank facilities rating to BB+ from BBB-.
Positive global cues helped Indian markets climb crucial resistance levels for the week ended September 14, but the big move was seen in the small & midcaps space.
A list of stocks which are in focus because of their price action. The technical outlook is limited to near and medium-term.
In his address to shareholders in the Annual Report for 2018-19, Khorakiwala said the company has several new chemical entities (NCEs) which are being developed as antibiotic drugs that are at various stages of clinical trials.
Wockhardt has told investment firm Moelis & Company that it intends to sell a 40 percent stake.
The Mumbai-headquartered firm is now reaching out to strategic suitors and is exploring the sale of select brand portfolios, two sources familiar with ongoing negotiations told Moneycontrol.
Bioanalytical and quality systems of bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol ER tablets were audited, Wockhardt said.
Trends on SGX Nifty indicate a negative opening for the broader index in India, a fall of 26 points or 0.22 percent. Nifty futures were trading around 11,857-level on the Singaporean Exchange.
EudraGMDP is the name of the European Union database which inter-alia contains Good Manufacturing Practice certificates.
Decitabine is used to treat Myelodysplastic syndromes (MDS) -- a group of cancers in which immature blood cells in the bone marrow do not mature and, therefore, do not become healthy blood cells.
The product is being manufactured at a contract manufacturing facility, based near Flyderabad, India.
One can look to go long around for a target of Rs.468 in the coming weeks. The stop loss can be placed at Rs 395.80.
After a disastrous 2017-18, there are signs of recovery in FY19. In 9MFY19, sales grew 9 percent and net loss narrowed to Rs 180 crore from Rs 454 crore from last year.
Wockhardt's Imatinib Mesylate tablets are a generic version of Gleevec, marketed in USA and other countries by Novartis.
Sales during the quarter under review stood at Rs 1,125 crore, as against Rs 1,022 crore in the same quarter last year.
Equity markets around the globe have been under pressure on account of trade war fears, interest rate hike and valuation concerns
Wockhardt moved the court as its anti-inflammatory drug -- Ace Proxyvon -- is one of the FDC medicines affected by the Centre's September 7 notification banning 328 such combinations.
The special resolution seeking approval of the shareholders for issuance of NCDs up to Rs 1,200 crore on private placement basis was passed with 99.72 per cent of votes polled favouring the resolution, Wockhardt said in a filing to the BSE.
Wockhardt has reported a consolidated total income from operations of Rs 1,007.71 crore and a net loss of Rs 86.18 crore for the quarter ended Jun-2018